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Survivors of childhood cancer and other immunocompromised children are at high risk 
for the development of secondary Human Papillomavirus (HPV)-associated cancers.  In this 
overview, the authors examine the epidemiology of vaccine efficacy, the natural history of HPV 
infections, and accelerated HPV-associated cancer development in these populations.  The 









The high efficacy of the HPV vaccine in immunocompetent populations has translated 
into a resounding public health success in reducing HPV infection1-4 and cervical precancers.3,5-7  
However, in recent studies, vaccination against HPV in HIV positive (HIV+) persons does not 
appear to result in the same clinical protection from infection and diseases as in HIV negative 
(HIV-) persons.8-12  These concerning data led us to reflect on as yet unanswered questions about 
the natural history of HPV infection (latency and reactivation) in both immunocompetent and 
immunosuppressed populations13-15 and how these issues impact the predicted effectiveness of 
HPV vaccination in specific immunosuppressed subpopulations beyond HIV+ persons.  In 
particular, this narrative will focus on survivors of childhood cancer (those with and without 
bone marrow transplants) and solid organ transplant recipients. Consideration of non-HIV+, 
immunocompromised children and adolescents who are being immunized to protect from future 
HPV infection and diseases must be thoughtfully addressed.  This is especially true as there are 
concurrent changes to the standards of cervical cancer screening and the management of young 
and middle-aged women that are in place based on the presumption of homogeneity of risks and 
outcomes in HPV natural history. 
Observations 
Epidemiology and pathophysiology of primary HPV infections and their reactivation  
First, we must consider that, in addition to the differences between HIV- and HIV+ 
populations in their response to HPV infections and preventive HPV vaccinations, the HPV 
vaccine trials in HIV+ populations may not be reflective of or translatable to all 
immunocompromised populations.  Many of those participating in these clinical trials acquired 







acquisition – also a sexually transmitted infection.  Prospective studies on the natural history of 
HPV suggest that the first HPV acquisition takes place in women aged 15-19 years, with the 
peak prevalence of HPV at 20 -29 years of age.16 Thus if HIV+ is behaviorally acquired, the 
likelihood that a HIV+ person also has a prior history of HPV infection is high, making 
conclusions drawn from HPV vaccination studies more challenging to interpret.  As 
demonstrated in longitudinal studies, clinical trials of HIV+ individuals are at risk for 
reactivation of latent HPV infections acquired earlier.17,18  And yet, consistent with 
immunocompetent populations, HIV+ participants in HPV vaccine trials demonstrated that 
younger age at vaccination against HPV strongly correlated with higher antibody titers (HPV 16 
OR= -1.2 per 1 year increase in age).19  
Second, in animal model studies of cottontail rabbit papillomavirus, immunosuppression 
facilitated the reactivation of latent papillomavirus infections, prevented papilloma regression, 
and led to an elevation of the viral DNA copy number at sites of previous disease.20  Thus, not 
only is it important to consider the translatability of this animal model for human papillomavirus 
reactivation, especially among people who have been treated for cancer or received organ 
transplants, but when this group of individuals actually receives the vaccine in relationship to 
their age, clinicians must also consider their onset of sexual activity and the timing of their 
immunosuppressive therapy.  With this in mind, we will focus on the differences in the natural 
history of HPV infection and its associated-cancer development in cancer survivors and 








Epidemiology of HPV reactivation and disease progression in immunosuppressed cohort: cancer 
survivors 
Cancer treatment itself is genotoxic and places patients at future risk for secondary 
cancers.  Immunosuppression and inadequate humoral response from the cancer treatments may 
linger long-term, creating a milieu for accelerated cancer development and progression with 
HPV, either due to its reactivation or to acquiring a new primary infection (Figure 1B).  
Reactivation of other DNA viruses, such as Herpes Simplex Virus and Epstein-Barr virus, has 
been well documented.21,22  Biological and epidemiological evidence of HPV latency in humans 
has also been observed.15,23-26  After allogeneic stem cell transplantation (allo-SCT), long-term 
survivors are at increased risk for HPV-associated cancers.27  Studies have demonstrated an 
increased risk of cervical dysplasia in long-term survivors of allo-SCT compared to time periods 
before their transplant.28,29  Another complexity is 40-60% of allo-SCT patients develop graft 
versus host disease (GVHD).30  GVHD immunosuppressive therapy can be intensive and 
prolonged and likely augments the risk for HPV reactivation as seen in case studies.31-33  What is 
unclear is whether the GVHD itself, which can be inflammatory, promotes HPV reactivation 
similar to studies on chlamydia and HPV redetection after clearance,34 or the treatment of 
GVHD, which can be immunosuppressive, drives this augmented risk. Regardless of which, all 
of these risk factors (Figure 1B, red arrows) can accelerate the transition from infection to 
dysplasia, from latency to reactivation, and from dysplasia to HPV-associated cancers in patients 
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Epidemiology of HPV reactivation and disease progression in immunosuppressed cohort: solid 
organ transplant patients 
Beyond cancer treatment, further evidence of HPV latency and risk exists in solid organ 
transplant (SOT) recipients (Figure 1C).  People who have had SOT, similar to allo-SCT, are 
living longer.  With their improved longevity comes a new health risk – people with SOT have 
HPV-associated cancers at higher rates than healthy persons.35-37  In 2011, Engles, et al. 
examined the risk of secondary cancers for organ transplant patients using standardized 
incidence ratios (SIRs).  Cervical cancer, which is preventable by screening to detect and treat 
nonreportable precancers, had an SIR of only 1.03; however, cancer of the vulva, which is also 
HPV-associated but does not have an algorithm for screening and management, had an SIR of 
7.6.38  In a study of women with renal transplants, there was a higher prevalence of oral HPV and 
genital HPV compared to immunocompetent women, despite studies that suggest women with 
renal transplants were similar or even more conservative in their recent sexual behavior.39-41  
Similar patterns of increased risk of HPV-associated cancers in both the SOT recipients and 
HIV+ population, overlaid with the risk among cancer survivors and bone marrow transplant 
recipients, suggest that immune deficiency may be most responsible for this increased risk.14,42 
Like cancer patients, transplant patients are at risk of accelerated disease develop and 
progression, as well as poor clearance and latent infection reactivation, which lead to greater risk 
of HPV-associated cancers (Figure 1C, green arrows).  
Epidemiology of HPV reactivation and disease progression in immunosuppressed cohort: 
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The impact of other immunosuppressive conditions, such as Lupus, Crohn’s disease, or 
Rheumatoid Arthritis, on cervical abnormalities and cancer was examined in a 2013 review. The 
authors found that patients with end-stage renal disease were at higher risk for cervical cancer, 
and patients with autoimmune diseases (particularly those on medication for treatment) had an 
increased risk of precancerous lesions.43 Data also suggest that even episodic periods of 
immunosuppression in otherwise healthy women may also contribute to reactivation. One 
example of this is HR-HPV infection and cytological abnormalities are detected more often in 
pregnant women.44,45 In a study of 274 pregnant women matched on age to 1060 nonpregnant 
women, HR-HPV was detected in 38.2% of the pregnant women compared to 14.2% in the 
nonpregnant women. In their multivariate analysis, pregnancy increased the odds of an HPV 
infection more than 3-fold (OR=3.5).46 
Understanding the differences between immunocompromised populations, with regard to 
reactivation of latent HPV infections, risk of new HPV acquisition, and speed of cancer 
development and progression, will be key to the development of best screening practices for 
them.  If, in fact, non-HIV+ immunocompromised persons are at a higher risk for reactivation of 
latent viruses compared to immunocompetent persons, and equivalently or even at greater risk 
compared to HIV+ populations, then vaccination and screening at an ideal time and in an ideal 
manner will be essential for prevention of secondary, HPV-associated cancers.  We discuss these 
prevention strategies below (see Figure 1 for preventions strategies in italics).  
Efficacy of the vaccine in immunosuppressed cohorts 
It must be emphasized that the presumed main function of vaccine-induced HPV 
antibodies is to prevent HPV entry into cells. The antibody titers gained by HPV vaccination in 
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populations, and this suggests that vaccination should be an effective prevention modality for 
both groups.9,10,19  However, in natural history studies of HIV+ women, newly detected HPV 
infections can be found even in the absence of current sexual activity, and this risk is 
proportionate to decreasing CD4+ T-cell count and increasing HIV viral load.47  These HPV 
detections deemed “incident” may in fact not be new infections but instead the reactivation of a 
latent or quiescent HPV infection that had been controlled previously through T-cell mediated 
immune responses.18  These data suggest that, in people with an increased risk of prior HPV 
exposure, most new detection and disease onset may indeed not be from a true new infection, 
where the humoral response has failed; rather, it may be detection of a newly reactivated 
infection that cannot be suppressed through HPV vaccination, as antibodies derived from HPV 
vaccination do not function in clearing or eradicating previous established infections.  When the 
quadrivalent HPV vaccine was administered to HIV+ children aged 7 to 12, seroconversion rates 
were greater than 96%48; therefore the immunization is leading to the type-specific antibodies 
that are detectable and quantifiable. A recent study in Lupus patients found that the HPV vaccine 
was safe and immunogenic,49 extending seroconversion data to non-HIV+ populations that 
experience periods of immunosuppression. Determining how to apply these natural history 
findings to other immunosuppressed subpopulations, like SCT and SOT patients, and their 
implications on approaches to and timing of vaccination as a primary HPV prevention strategy, 
will require thoughtful attention.  
In immunocompetent populations, the HPV vaccine is highly cost-effective when 
administered before sexual debut, but that decreases with increased age.50 The cost-effectiveness 
of the HPV vaccine in non HIV+ immunocompromised populations has not been determined; 
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testing clnics in men who have sex with men (MSM). The authors stated that offering 
vaccination to HIV+ MSM up to the age of 40 years is likely to be cost-effective.51 With that in 
mind, the cost-effectiveness of the HPV vaccine in male or female immunosuppressed 
populations likely should be even more cost-effective, relative to the general population, due to 
their increased burden of disease and their healthcare costs.  
The 2017 position paper of the International Papillomavirus Society recommends a 3 
dose regimen to all immunocompromised people, preferably before they become 
immunocompromised.52 Additional data published in the last year has examined HPV vaccine 
responses in immunosuppressed patients, and the findings support the 2017 position paper. A 
Phase 1 quadrivalent HPV vaccine trial was conducted in allo-SCT patients 1.2 (median) years 
posttransplant. In this study, antibody responses were demonstrated in 78.3% of patients 
receiving immunosuppression and in 95.2% patients not receiving immunosuppression.53 
Seroconversion to the quadrivalent HPV vaccine was also recently examined in adolescents 
before and after kidney transplantation. Those vaccinated after transplantation had lower 
seroconversion rates than those with chronic kidney disease, regardless of whether they received 
dialysis or not, suggesting that their immunosuppression directly impacted their ability to 
seroconvert.54  
These findings lead to this question:  Do children, who have had a SCT or received a 
transplanted organ and subsequently are fully revaccinated, merit more frequent clinical follow-
up for HPV diseases than the general population?  Those with SCT have bone marrow that has 
been fully repopulated with new cells.  This naïve bone marrow requires a repeat of a patient’s 
childhood and adolescent vaccination series to reestablish their protective humoral response.  
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immunosuppression is tapered to be minimal; however, the need for chronic 
immunosuppression, or intermittent high dose suppressive therapy, likely would result in a more 
muted protection.   
Problems and ideas for future research:  when and how to we vaccinate?   
Most alarmingly, survivors of pediatric and young adult cancers (PYAC) have an excess 
relative risk for HPV-associated malignancies,55 yet have a low HPV vaccine initiation rate.56  In 
an active clinical trial, 679 adolescent and young adult cancer survivors had an HPV vaccine 
initiation rate of 22% for 13-17 year olds and 26% for 18-26 year olds.57  This is surprising as the 
vaccine has been recommended for PYAC survivors by the Children’s Oncology Group’s Long-
Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult cancer 
since 2008.57,58  One study observed that survivors of PYAC had later sexual debuts, but still 
over 90% report sexual activity.59  Some studies have reported risky sexual behaviors, such as 
not using condoms due to perceived infertility from their cancer treatments.60  When compared 
to sibling controls, PYAC survivors engaged in risky sexual behavior at the same rate as their 
siblings,61 yet were less likely to have received a Pap smear within the last 3 years.62  If PYAC 
survivors only see their oncologist, and are less likely to see primary healthcare practitioners or 
gynecologists, could this be a reason for the low vaccine and screening rates?  Are there 
opportunities to increase vaccination and screening in the oncologist’s office?  
For allo-SCT, the 2015 guidelines from the International Consensus Project on Clinical 
Practice in Chronic GVHD provide a ‘should generally be offered’ HPV immunization 
recommendation to young women 12-26 years after the transplantation, if they have not already 
received any or all vaccine doses.63  This recommendation falls well short of stating all allo-SCT 
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vaccine naïve.  When considering which vaccines to include, it is not clear if the vaccine 
schedule includes the HPV vaccine in the same way other vaccines are recommended 3 to 24 
months posttransplant, such as Hepatitis B or pneumococcal conjugate.64  With changing 
guidelines, is there any indication that allo-SCT patients still would need 3 doses versus the 
recommended 2 in the younger patients?  A current phase IV clinical trial65 is underway for 
safety and efficacy of HPV vaccination 6 to 12 months post allo-SCT with a 3 dose schedule. 
This study’s findings will likely guide better recommendations based on stronger evidence. 
Children with an SOT may be at even greater risk for inadequate primary HPV protection 
due to waning HPV vaccine efficacy because they will require lifelong immunosuppressive 
medications to avoid organ rejection.  These medications may also lead to reactivation of a latent 
HPV infection.  There are several guidelines for management of solid organ transplant patients 
specific to HPV, but much of the natural history behind these management guidelines is still 
unknown.  HPV vaccine administered 5 months after transplant yielded an overall seroresponse 
to any HPV type at 62% for the quadrivalent vaccine.66  Guidelines from the American Society 
of Transplantation state that vaccination of eligible patients is preferred prior to transplantation, 
based on the hypothesis that an antibody response to vaccination would be more robust.67  Could 
this recommendation be extended to those younger than age 9 and those older than age 26?  The 
corollary question -- how protective is the humoral response as one starts to receive 
immunosuppressive or dialysis prior to transplant? -- is another unknown. In a recent review, 
attention is drawn to the need for research in the post transplant period. The authors suggest 
research studies to better understand the immune response in post transplant patients in order to 
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uptake in the general population, which reduces herd immunity protection, they urge the 
prioritization of immunizations, including HPV, in transplant patients.68  
With this background in mind, it is important to ask ourselves to consider different 
approaches to accelerate prophylactic HPV vaccination among transplant populations. Are there 
opportunities for the specialist to become the vaccinator in order to increase HPV vaccination 
rates when children are waiting for transplants?  Strategies for vaccination of patients 
pretransplantation, and a possible need for future revaccination, should be further examined. 
Finally, returning to patients who were treated for cancer during their childhood, when 
examining reasons for low vaccine uptake in these young women, physician recommendation 
and familial HPV communication were found to be associated with an increased likelihood of 
vaccine initiation.69 Another study in PYAD survivors found that younger age at cancer 
diagnosis (under 15 years old), and a shorter interval from diagnosis to vaccine eligibility, were 
more likely to start the vaccination series.70 This may be reflective of primary healthcare 
practitioners following regular vaccination guidelines or primary healthcare practitioners who are 
unfamiliar with specific vaccination recommendations for these patients. Other considerations, 
such as vaccine storage in nonprimary care clinic sites, must also be addressed if oncologists or 
transplant physicians would initiate a vaccination program. 
Problems and ideas for future research:  when and how do we screen for HPV-related diseases?   
Recognizing that primary and secondary prevention strategies are both integral parts of 
cancer prevention, we must consider how and when to screen all immunocompromised patients 
for HPV infections and disease (Figure 1, italics).  Recent guidelines suggest that screening for 
cervical cancer in SOT and SCT patients should mirror the screening of women with HIV.67,71  
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to more intensive screening that mirrors reinitiation of screening, beginning with repeated yearly 
exams.71  Other populations at risk for immunosuppression could benefit from information 
gained in allo-SCT and SOT recipients, such as those with Lupus or Fanconi Anemia.  They may 
manifest with similar risk for HPV, or require more specific recommendations, in regards to 
vaccination and screening.  The outcomes from variations in screening algorithms will need to be 
examined in clinical trials and within the context of vaccination status and serologic titers.72  
Observational data from international screening programs that utilize HPV testing can also be 
analyzed to understand positivity rates and disease over time, and ultimately better guidance on 
future screening. However, developing an algorithm for screening and management of cancer, 
SCT, and SOT patients needs to based on the acknowledgement that these patients may 
inherently have cellular DNA damage and chronic or episodic immune system activation and 
immunosuppression, all of which could place these patients at greater risk for inferior HPV 
vaccination protection, accelerated reactivation of a latent HPV infection, poorer clearance of a 
HPV infection, and rapid progression from infection to dysplasia to cancer.   
Discussion 
We must understand if there are subpopulations of children and adolescents who may not 
be completely protected against HPV by vaccination, a primary prevention strategy for the 
general population that should be universally endorsed.  We also must determine if HPV 
infection, latency, and reactivation are more likely to occur in subpopulations of high-risk 
children and adolescents, and determine ways to migitate that risk before infection and during 
disease progression.  Future research efforts should focus on each of these groups -- survivors of 
allo-SCT, all childhood cancers, and SOT -- to better understand the HPV vaccine efficacy in 
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the possible utility of HPV vaccine boosters.  These research efforts will permit a transition from 
acknowledging the potential inherent risk within these groups to the quantifiable determination 
of their true risk and the effective migitating actions that will reduce that risk. Current guidance 
from the Advisory Committee on Immunization Practices on HPV vaccination for adults with 
preexisting risks provides “shared decision making” instead of clear guidance for populations 
with underlying risks.73 Ambiguity in recommendations can lead to both missed vaccination 
opportunities with the added burden of a lack of insurance coverage. There is great potential in 
large pediatric national registries, such as the Center for International Blood and Marrow 
Transplantation, the North American Pediatric Renal Trials and Collaborative Trials, or 
Improving Renal Outcomes Collaborative, to determine best practices. The single current 
strategy that we know will protect survivors of childhood cancer in preventing secondary HPV-
associated cancers is to achieve a high vaccination rate in the general population; with high 
vaccination rates, immunosuppressed persons will gain benefit through herd immunity at a 
minimum.  All physicians and healthcare providers should support on-time, routine vaccination 
of young adolescents and put vaccination of higher risk groups, such as those who are 
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Figure 1. The natural history of HPV infection, clearance, latency, dysplasia, and cancers and 
prevention strategies (in italics) for HPV-associated cancers. A. The natural history and 
prevention strategies for the general population. B. The differences in natural history (red 
arrows) and prevention strategies in cancer patients. C. The differences in natural history (green 
arrows) and prevention strategies in transplant patients.  
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